Le Lézard
Classified in: Health
Subjects: RCL, CFG

Advisory - One lot of the hypoglycemia treatment Glucagon recalled as it may pose serious health risks


OTTAWA, Sept. 25, 2021 /CNW/ -

Summary

Product: Glucagon (DIN 02243297, lot D239382A, expiry May 10, 2022)

Issue: Eli Lilly Canada Inc. is recalling one lot of Glucagon, following a complaint that a vial from this lot was found to be in liquid form instead of powder form. Glucagon normally comes in a powder form with accompanying diluting solution and should be used immediately after mixing.

What to do: Do not use product from this lot. Call 9-1-1 immediately if you or a family member, including children, have taken this product and are experiencing medical issues, such as hypoglycemia (low blood sugar) or seizures. Consult with your doctor or pharmacist if you have any questions or concerns about the product you are taking.

Issue

Eli Lilly Canada Inc. is recalling one lot of Glucagon (D239382A, expiry May 10, 2022), following a complaint that a vial from this lot was found to be in liquid form rather than powder form. Glucagon normally comes in a powder form with accompanying diluting solution, and should be used immediately after mixing. Other vials in the lot may be affected.

Vials from the affected lot may not work as intended in treating patients with hypoglycemia (low blood sugar) resulting in persisting hypoglycemia. It could also cause other serious health consequences, such as unconsciousness and seizures.

Glucagon is a prescription drug administered by injection for the emergency treatment of severe hypoglycemia (unconsciousness due to low blood sugar), which may occur in diabetic patients (children and adults) treated with insulin.

Health Canada is monitoring the effectiveness of the company's recall and the implementation of any necessary corrective and preventative actions.

What consumers should do

Affected products

Company

Product Name/Active Pharmaceutical Ingredient (API)

DIN

Lot

Expiry

Eli Lilly

Glucagon

02243297

D239382A

May 10, 2022

Photos  

Glucagon (DIN 02243297, lot D239382A, expiry May 10, 2022) (CNW Group/Health Canada)

Glucagon (DIN 02243297, lot D239382A, expiry May 10, 2022) (CNW Group/Health Canada)

Également disponible en français

SOURCE Health Canada


These press releases may also interest you

at 09:10
Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today the appointment of Geraldine Usseglio as Head of Human Resources. The creation of this position reinforces the ongoing...

at 09:10
MMS Holdings (MMS) ? a data-focused CRO ? provided regulatory strategy support to Praxis Bioresearch in the development of a therapeutic for apathy in Alzheimer's disease. This comes as Praxis was awarded a $2.9 Million Fast-Track SBIR Grant to...

at 09:06
BioLabs, the definitive growth partner for science-based entrepreneurs, today announced it has named Dr. Nina Dudnik the new Chief Business Officer. Dudnik, a former BioLabs board member, leader in innovation and entrepreneurship and inspirational...

at 09:05
In support of ALYN Hospital, Israel's only pediatric and adolescent rehabilitation center, more than 70 cyclists gathered on the Eastern Shore of Maryland for the Wheels of Love charity bike from Oct. 24 ? 26. Riders who participated in the multi-day...

at 09:03
Avantor, Inc. , a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, announced that it has opened a new single-use facility in Hillegom,...

at 09:00
UpHealth, Inc. ("UpHealth" or the "Company"), a global digital health company delivering technology platforms, infrastructure, and services to modernize care delivery and health management, today announced that it will release financial results for...



News published on 25 september 2021 at 20:33 and distributed by: